Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Roche Seeks to Extend Antitrust Waiting Period for Illumina Bid

This article has been updated from a previous version to clarify that Roche is seeking to extend the antitrust waiting period for its bid, not the timeline for the tender offer.

NEW YORK (GenomeWeb News) – Roche is seeking to extend the antitrust waiting period required for its $5.7 billion hostile bid for Illumina, it said in a document filed with the US Securities and Exchange Commission.

In the filing, Roche said it will file necessary paperwork on Feb. 27 to extend the required waiting period under the Hart-Scott-Rodino at to expire at the end of the day March 13. The US Antitrust Division or Federal Trade Commission may further extend the waiting period, Roche noted in the filing.

Roche is offering $44.50 per share of Illumina's stock. Illumina has rejected the bid and implemented a poison pill plan. Roche named its nominees for Illumina's board a few weeks ago as part of its hostile bid.

Shareholders have filed a lawsuit against Illumina alleging conflict of interest and breach of fiduciary responsibilities.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.